Kazia Therapeutics CFO James Levine Awarded 200,000 Stock Options

This Form 4 filing discloses that James E. Levine, Chief Financial Officer of Kazia Therapeutics Ltd, was awarded 200,000 employee stock options on June 19, 2026. The options have an exercise price of $13.86 per ADS and expire on June 19, 2029. The vesting schedule is structured with one-third of the options vesting on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vesting in equal yearly tranches on the anniversary of the Commencement Date. The filing includes a forfeiture provision stating that all options will be forfeited if Mr. Levine voluntarily departs prior to the first anniversary of the Commencement Date. The options were granted for no consideration and represent a standard equity compensation arrangement for a corporate officer.